The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Open accessAbstract
BACKGROUND: The discovery of low-frequency coding variants affecting the risk of coronary artery disease has facilitated the identification of therapeutic targets. METHODS: Through DNA genotyping, we tested 54,003 coding-sequence variants covering 13,715 human genes in up to 72,868 patients with coronary artery disease and 120,770 controls who did not have coronary artery disease. Through DNA sequencing, we studied the effects of loss-of-function mutations in selected genes. RESULTS: We confirmed previously observed significant associations between coronary artery disease and low-frequency missense variants in the genes LPA and PCSK9. We also found significant associations between coronary artery disease and low-frequency missense variants in the genes SVEP1 (p.D2702G; minor-allele frequency, 3.60%; odds ratio for disease, 1.14; P=4.2×10(-10)) and ANGPTL4 (p.E40K; minor-allele frequency, 2.01%; odds ratio, 0.86; P=4.0×10(-8)), which encodes angiopoietin-like 4. Through sequencing of ANGPTL4, we identified 9 carriers of loss-of-function mutations among 6924 patients with myocardial infarction, as compared with 19 carriers among 6834 controls (odds ratio, 0.47; P=0.04); carriers of ANGPTL4 loss-of-function alleles had triglyceride levels that were 35% lower than the levels among persons who did not carry a loss-of-function allele (P=0.003). ANGPTL4 inhibits lipoprotein lipase; we therefore searched for mutations in LPL and identified a loss-of-function variant that was associated with an increased risk of coronary artery disease (p.D36N; minor-allele frequency, 1.9%; odds ratio, 1.13; P=2.0×10(-4)) and a gain-of-function variant that was associated with protection from coronary artery disease (p.S447*; minor-allele frequency, 9.9%; odds ratio, 0.94; P=2.5×10(-7)). CONCLUSIONS: We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“rare loss-of-function mutations in the lipoprotein lipase (LPL) gene are associated with higher plasma triglyceride levels and a higher risk of cardiovascular disease”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while rare, loss-of-function mutations in the APOC3, ANGPTL3, and ANGPTL4 genes, which encode for natural inhibitors of LPL, are associated with lower triglyceride levels and a corresponding lower risk of cardiovascular disease.[9][10][11][12][13]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35”
The cited source says what the claim attributes to it.
In the citing paper
“ANGPTL4 loss-of-function mutations in humans are associated with lower plasma triglycerides (40, 56–58).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, multiple studies found that individuals deficient in one of these three ANGPTL proteins have a lower risk of cardiovascular disease (56, 57, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [57]
In the citing paper
“large-scale genetic studies have shown that individuals carrying loss-of-function mutations in ANGPTL4 exhibit a lower risk of coronary artery disease compared to noncarriers [34,35].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [34]
In the citing paper
“Similarly, heterozygous LOF variants in ANGPTL311 and ANGPTL412 genes are associated with reductions both in plasma TG and ASCVD risk.”
From Clinical review on triglycerides (2020) · cites this paper as [12]
In the citing paper
“Genetically attenuated ANGPTL4 is associated with favourable lipid and glycaemia profiles, and with reduced ASCVD risk.12,99”
From Clinical review on triglycerides (2020) · cites this paper as [12]
In the citing paper
“defects in genes controlling TG metabolism, including APOC3, ANGPTL3 and ANGPTL4 that have been linked to reduced TG and are associated with reduced coronary calcification25 or reduced CVD risk.26-30”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [29]
In the citing paper
“Like mice, humans deficient in ANGPTL3, ANGPTL4, or ANGPTL8 have lower plasma triglycerides (56–58, 163–166).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics · doi:10.1038/ng.784 · Cited by 1,866
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease
Nikpay, M., Goel, A., Won, H., Hall, L. M., Willenborg, C., Kanoni, S., Saleheen, D., Kyriakou, T., Nelson, C. P., Hopewell, J. C., et al. (2015) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 581
Cited by
Sorted by citations
Items 201–300 of 497
Triglycerides and Open Angle Glaucoma – A Meta-analysis with meta-regression
Pertl, L., Mossböck, G., Wedrich, A., Weger, M., Königsbrügge, O., Silbernagel, G., & Posch, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-08295-1 · Cited by 31
Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease
Shu, L., Blencowe, M., & Yang, X. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00056 · Cited by 31
Genetic Determinants of Peripheral Artery Disease
Klarin, D. M., Tsao, P. S., & Damrauer, S. M. (2021) · Circulation Research · doi:10.1161/circresaha.121.318327 · Cited by 33
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 33
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?
Olshan, D. S., & Rader, D. J. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.012 · Cited by 30
SVEP1 is an endogenous ligand for the orphan receptor PEAR1
Elenbaas, J. S., Pudupakkam, U., Ashworth, K. J., Kang, C. J., Patel, V., Santana, K., Jung, I., Lee, P. C., Burks, K. H., Amrute, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36486-0 · Cited by 30
Integrating Genes Affecting Coronary Artery Disease in Functional Networks by Multi-OMICs Approach
Vilne, B., & Schunkert, H. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00089 · Cited by 31
Triglycerides and endothelial function: molecular biology to clinical perspective
Kajikawa, M., & Higashi, Y. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000630 · Cited by 29
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 32
Rong, B., Wu, Q., Reiter, R. J., & Sun, C. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.06.024 · Cited by 30
Yin, S., Xu, H., Xia, J., Lü, Y., Xu, D., Sun, J., Wang, Y., Wang, L., & Sun, G. (2023) · Advances in Nutrition · doi:10.1016/j.advnut.2023.09.010 · Cited by 30
The Future of Cardiovascular Therapeutics
MacRae, C. A., Roden, D. M., & Loscalzo, J. (2016) · Circulation · doi:10.1161/circulationaha.116.023555 · Cited by 29
Can targeting ANGPTL proteins improve glucose tolerance?
Davies, B. S. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4604-4 · Cited by 30
Deng, M., Kutrolli, E., Sadewasser, A., Michel, S., Joibari, M. M., Jaschinski, F., Olivecrona, G., Nilsson, S. K., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100237 · Cited by 30
Yang, L., Yu, C., Wang, X., Yuan, S., Zhang, L., Lang, J., Zhao, D., & Feng, Y. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005973 · Cited by 24
Wen, Y., Zhang, X., Liu, H., Ye, H., Wang, R., Ma, C., Duo, T., Wang, J., Yang, X. Z., Yu, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02520-8 · Cited by 31
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 28
Jiao, X., He, J., Yang, Y., Yang, S., Li, J., & Qin, Y. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0736-6 · Cited by 29
Azzo, J. D., Dib, M., Zagkos, L., Zhao, L., Wang, Z., Chang, C.-P., Ebert, C., Salman, O., Gan, S., Zamani, P. L., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011146 · Cited by 26
Regulation of angiopoietin-like 4 and lipoprotein lipase in human adipose tissue
Dijk, W., Schutte, S., Aarts, E. O., Janssen, I. M. C., Afman, L. A., & Kersten, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.006 · Cited by 30
Genome-Wide Association Studies of Coronary Artery Disease: Recent Progress and Challenges Ahead
Clarke, S. L., & Assimes, T. L. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0748-4 · Cited by 27
Schmidt, A. F., Joshi, R., Gordillo‐Marañón, M., Drenos, F., Charoen, P., Giambartolomei, C., Bis, J. C., Gaunt, T. R., Hughes, A. D., Lawlor, D. A., et al. (2023) · Communications Medicine · doi:10.1038/s43856-022-00234-0 · Cited by 30
A large‐scale exome array analysis of venous thromboembolism
Lindström, S., Brody, J. A., Turman, C., Germain, M., Bartz, T. M., Smith, E. N., Chen, M., Puurunen, M. K., Chasman, D. I., Hassler, J., et al. (2019) · Genetic Epidemiology · doi:10.1002/gepi.22187 · Cited by 28
Genetic Polymorphisms in Sepsis and Cardiovascular Disease
Nakada, T., Takahashi, W., Nakada, E., Shimada, T., Russell, J. A., & Walley, K. R. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.01.003 · Cited by 26
Yang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26
Calcineurin inhibitors ameliorate PAN ‐induced podocyte injury through the NFAT–Angptl4 pathway
Shen, X., Zhang, Y., Lin, C., Weng, C., Wang, Y., Feng, S., Wang, C., Shao, X., Lin, W., Li, B., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5512 · Cited by 26
Norby, F. L., Tang, W., Pankow, J. S., Lutsey, P. L., Alonso, Á., Steffen, B. T., Chen, L. Y., Zhang, M. J., Shippee, N. D., Ballantyne, C. M., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.08.064 · Cited by 27
ANGPTL4 Regulates Psoriasis via Modulating Hyperproliferation and Inflammation of Keratinocytes
Zuo, Y., Dai, L., Li, L., Huang, Y., Liu, X., Liu, X., Duan, X., Jiang, S., Deng, G., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850967 · Cited by 27
Inflammation-Related Risk Loci in Genome-Wide Association Studies of Coronary Artery Disease
Mauersberger, C., Schunkert, H., & Sager, H. B. (2021) · Cells · doi:10.3390/cells10020440 · Cited by 27
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
Emerging Targets for Cardiovascular Disease Prevention in Diabetes
Stitziel, N. O., Kanter, J. E., & Bornfeldt, K. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.011 · Cited by 28
Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE−/− mice
Jiao, X., Yang, Y., Li, L., Yu, H., Yang, Y., Li, J., Du, Y., Zhang, J., Hu, C., & Qin, Y. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.06.014 · Cited by 26
Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity
Sun, T., Zhan, W., Wei, L., Xu, Z., Li, F., Yang, Z., Wang, C., & Zhang, J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01580-z · Cited by 25
Human Plasma Proteome During Normal Pregnancy
Tarca, A. L., Romero, R. J., Bhatti, G., Gotsch, F., Done, B., Gudicha, D. W., Gallo, D. M., Jung, E., Piqué-Regi, R., Berry, S. M., et al. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00391 · Cited by 27
Salisbury-Ruf, C. T., Bertram, C. C., Vergeade, A., Lark, D. S., Shi, Q., Heberling, M. L., Fortune, N. L., Okoye, G. D., Jerome, W. G., Wells, Q. S., et al. (2018) · eLife · doi:10.7554/elife.40907 · Cited by 25
Increased Level of Angiopoietin Like Proteins 4 and 8 in People With Sleep Apnea
Alterki, A., Abu‐Farha, M., Al‐Khairi, I., Cherian, P., Devarajan, S., Shyamsundar, A., Ali, S., Al‐Mulla, F., Tuomilehto, J., & Abubaker, J. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00651 · Cited by 26
Landfors, F., Chorell, E., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100313 · Cited by 24
Golbus, J. R., Stitziel, N. O., Zhao, W., Xue, C., Farrall, M., McPherson, R., Erdmann, J., Deloukas, P., Watkins, H. C., Schunkert, H., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001374 · Cited by 25
The Inherited Basis of Coronary Artery Disease
Schunkert, H., Natarajan, P., & Samani, N. J. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2405153 · Cited by 23
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 23
Chronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice
Spitler, K. M., Shetty, S. K., Cushing, E. M., Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00144.2021 · Cited by 23
Ghasemzadeh, Z., Abdi, H., Asgari, S., Tohidi, M., Khalili, D., Valizadeh, M., Moeini, S., Eidkhani, V., Azizi, F., & Hadaegh, F. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0102-1 · Cited by 23
Genetics links between transforming growth factor β pathway and coronary disease
Zeng, L., Dang, T. A., & Schunkert, H. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.029 · Cited by 24
Angiopoietin-like 4: A molecular link between insulin resistance and rheumatoid arthritis
Masuko, K. (2016) · Journal of Orthopaedic Research® · doi:10.1002/jor.23507 · Cited by 24
Cardioinformatics: the nexus of bioinformatics and precision cardiology
Khomtchouk, B. B., Tran, D.-T. T., Vand, K. A., Might, M., Gozani, O., & Assimes, T. L. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz119 · Cited by 23
Variants inANGPTL4and the Risk of Coronary Artery Disease
Morrison, A. R., Fu, Y., & O’Donnell, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1607380 · Cited by 24
ANGPTL4 attenuates palmitic acid-induced endothelial cell injury by increasing autophagy
Zhan, W., Tian, W., Zhang, W., Tian, H., & Sun, T. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110410 · Cited by 22
Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 24
ANGPTL4 T266M variant is associated with reduced cancer invasiveness
Tan, Z. W., Teo, Z. Q., Tan, C., Choo, C. C., Loo, W. S., Song, Y., Tam, Z. Y., Ng, S. P., Koh, D. H. Z., Ng, Y. S., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.06.010 · Cited by 22
Effect of Glucagon on Ischemic Heart Disease and Its Risk Factors: A Mendelian Randomization Study
Ng, J. C. M., & Schooling, C. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa259 · Cited by 23
Genetic association studies in cardiovascular diseases: Do we have enough power?
Auer, P. L., & Stitziel, N. O. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.03.005 · Cited by 21
Perrot, N., Pelletier, W., Bourgault, J., Couture, C., Li, Z., Mitchell, P. L., Ghodsian, N., Bossé, Y., Thériault, S., Mathieu, P., et al. (2021) · Aging Cell · doi:10.1111/acel.13497 · Cited by 20
Angiopoietin-like 3: An important protein in regulating lipoprotein levels
Burks, K. H., Basu, D., Goldberg, I. J., & Stitziel, N. O. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101688 · Cited by 21
Paquette, M., Bernard, S., & Baass, A. W. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.02.008 · Cited by 21
Triglycerides and cardiovascular risk: Apolipoprotein B holds the key
Stock, J. K. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.004 · Cited by 21
Precision Medicine Approaches to Vascular Disease
Miller, C. L., Kontorovich, A., Hao, K., Ma, L., Iyegbe, C. O., Björkegren, J., & Kovacic, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.001 · Cited by 24
Angiopoietin-like protein 4 and cardiovascular function in COPD
Waschki, B., Kirsten, A., Holz, O., Meyer, T. S., Lichtinghagen, R., Rabe, K. F., MAGNUSSEN, H., Welte, T., Watz, H., & Janciauskiene, S. M. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2016-000161 · Cited by 21
The emerging Janus face of SVEP1 in development and disease
Elenbaas, J. S., Jung, I., Coler-Reilly, A. L. G., Lee, P. C., Alisio, A. E., & Stitziel, N. O. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.002 · Cited by 21
Nordestgaard, A. T., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf337 · Cited by 22
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 22
Tajima, T., Morita, H., Ito, K., Yamazaki, T., Kubo, M., Komuro, I., & Momozawa, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-26453-x · Cited by 19
Genome-wide discovery for biomarkers using quantile regression at biobank scale
Wang, C., Wang, T., Kiryluk, K., Wei, Y., Aschard, H., & Ionita‐Laza, I. (2024) · Nature Communications · doi:10.1038/s41467-024-50726-x · Cited by 23
Oni‐Orisan, A., Haldar, T., Cayabyab, M. A. S., Ranatunga, D. K., Hoffmann, T. J., Iribarren, C., Krauss, R. M., & RISCH, N. J. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2715 · Cited by 18
Advances in new therapeutic targets for atherosclerosis
Tang, W. H. W., & Hazen, S. L. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.216 · Cited by 18
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 23
Katanasaka, Y., Saito, A., Sunagawa, Y., Sari, N., Funamoto, M., Shimizu, S., Shimizu, K., Akimoto, T., Ueki, C., Kitano, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092449 · Cited by 19
The integrin ligand SVEP1 regulates GPCR‐mediated vasoconstriction via integrins α9β1 and α4β1
Morris, G. E., Denniff, M. J., Karamanavi, E., Andrews, S., Kostogrys, R. B., Bountziouka, V., Najafabadi, M. G., Shamkhi, N., McConnell, G., Kaiser, M., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15921 · Cited by 21
Khan, S. U., Saeed, S., Alsuhaibani, A. M., Fatima, S., Rehman, K. U., Zaman, U., Ullah, M., Refat, M. S. E.-D., & Lu, K. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101821 · Cited by 19
Girelli, D., Piubelli, C., Martinelli, N., Corrocher, R., & Olivieri, O. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.03.019 · Cited by 18
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Impact of loss-of-function in angiopoietin-like 4 on the human phenome
Gagnon, E., Bourgault, J., Gobeil, É., Thériault, S., & Arsenault, B. J. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117558 · Cited by 17
Protein O-Fucosyltransferases: Biological Functions and Molecular Mechanisms in Mammals
Hao, H., Eberand, B. M., Larance, M., & Haltiwanger, R. S. (2025) · Molecules · doi:10.3390/molecules30071470 · Cited by 18
ANGPTL4: A Comprehensive Review of 25 Years of Research
Ramos, P., Shi, Q., Kleberg, J., Maharjan, C. K., Zhang, W., & Kolb, R. H. (2025) · Cancers · doi:10.3390/cancers17142364 · Cited by 20
Huang, L., Cai, X., Lian, F., Zhang, L., Kong, Y., Cao, C., Ma, H., Shao, Y., Wu, Y., Zhang, B., et al. (2018) · Environmental Health and Preventive Medicine · doi:10.1186/s12199-018-0719-y · Cited by 17
Hariharan, P., & Dupuis, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-95637-9 · Cited by 17
Saad, M., El-Menyar, A. A., Kunji, K. B., Ullah, E., Suwaidi, J. M. S. A., & Kullo, I. J. (2022) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.122.003712 · Cited by 16
The Integrated Landscape of Biological Candidate Causal Genes in Coronary Artery Disease
Zheng, Q., Ma, Y., Chen, S., Che, Q., & Chen, D. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00320 · Cited by 15
Patel, A. P., & Natarajan, P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz032 · Cited by 18
Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 20
Lipoprotein Lipase: Structure, Function, and Genetic Variation
Perera, S. D., Wang, J., McIntyre, A. D., & Hegele, R. A. (2025) · Genes · doi:10.3390/genes16010055 · Cited by 17
Association Analysis and Meta-Analysis of Multi-Allelic Variants for Large-Scale Sequence Data
Jiang, Y., Chen, S., Wang, X., Liu, M., Iacono, W. G., Hewitt, J. K., Hokanson, J. E., Krauter, K. S., Laakso, M., Li, K. W., et al. (2020) · Genes · doi:10.3390/genes11050586 · Cited by 18
Yang, Q., Yin, R., Cao, X., Huang, F., Zhou, Y., & Chen, W. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0308-5 · Cited by 16
Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism
Hughes, M., Lenighan, Y. M., Godson, C., & Roche, H. M. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00148 · Cited by 16
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 18
Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients
Wang, T., Xu, J., Fu, L., & Li, L. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13508 · Cited by 17
Aarsetoey, R., Ueland, T., Aukrust, P., Michelsen, A. E., de la Fuente, R. L., Pönitz, V., Brügger‐Andersen, T., Grundt, H., Staines, H., & Nilsen, D. W. T. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13339 · Cited by 15
Atherosclerosis revisited from a clinical perspective: still an inflammatory disease?
Santovito, D., & Weber, C. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0770 · Cited by 15
The Genetics of Ischemic Heart Disease: From Current Knowledge to Clinical Implications
Elosúa, R., & Sayols-Baixeras, S. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.02.046 · Cited by 16
Mutai, H., Momozawa, Y., Kamatani, Y., Nakano, A., Sakamoto, H., Takiguchi, T., Nara, K., Kubo, M., & Matsunaga, T. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02262-4 · Cited by 15
Proteomic Associations of Adverse Outcomes in Human Heart Failure
Dib, M., Levin, M. G., Zhao, L., Diab, A., Wang, Z., Ebert, C., Salman, O., Azzo, J. D., Gan, S., Zamani, P. L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031154 · Cited by 15
Konjac Glucomannan Attenuated Triglyceride Metabolism during Rice Gruel Tolerance Test
Nagasawa, T., Kimura, T., Yoshida, A., Tsunekawa, K., Araki, O., Ushiki, K., Ishigaki, H., Shoho, Y., Suda, I., Hiramoto, S., et al. (2021) · Nutrients · doi:10.3390/nu13072191 · Cited by 15
Triglyceride Treatment in the Age of Cholesterol Reduction
Agrawal, N., Corradi, P. F., Gumaste, N., & Goldberg, I. J. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.08.003 · Cited by 15
Nind, T., Galloway, J., McAllister, G., Scobbie, D., Bonney, W., Hall, C., Tramma, L., Reel, P. S., Groves, M., Appleby, P., et al. (2018) · GigaScience · doi:10.1093/gigascience/giy060 · Cited by 15
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Do triglyceride-lowering drugs decrease risk of cardiovascular disease?
Maki, K. C., & Dicklin, M. R. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000424 · Cited by 14
Kjellqvist, S., Klose, C. D., Surma, M. A., Hindy, G., Mollet, I. G., Johansson, A., Chavaux, P., Gottfries, J., Simons, K., Melander, O., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004503 · Cited by 13
The genetic basis of sudden death in young people – Cardiac and non-cardiac
Li, F., Yin, P., & Xu, Z. (2021) · Gene · doi:10.1016/j.gene.2021.146067 · Cited by 14
Oldham, D., Wang, H., Mullen, J., Lietzke, E. E., Sprenger, K. G., Reigan, P., Eckel, R. H., & Bruce, K. D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.926631 · Cited by 14
Metadata
- Authors
- Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators
- Corresponding author
- Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-24
- Volume
- 374
- Issue
- 12
- Pages
- 1134-1144
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4850838
- OpenAlex
- W2294822677
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 26 · 2023: 26 · 2022: 50 · 2021: 63 · 2020: 58 · 2019: 52 · 2018: 58 · 2017: 69 · 2016: 44
- FWCI
- 60.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Figshare (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Massachusetts General Hospital (R01HL107816)
- Foundation for Barnes-Jewish Hospital
- Donovan Family Foundation
- University of Dundee
- Queen Mary University of London
- Wellcome Trust (098381, 090532, 090532/Z/09/Z, 090532/Z/09/)
- Deutsches Zentrum für Herz-Kreislaufforschung
- Massachusetts Medical Society
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research (NF-SI-0512-10165, NF-SI-0611-10170, NF-SI-0611-10099)
- British Heart Foundation (090532/Z/09/Z, RG/13/13/30194, RG/08/014/24067, RG/14/5/30893)
- University of Leicester
- University College London
- University of Oxford
- European Commission (EU-FP7, 261123, 098381)
- University of Glasgow
- Deutsche Forschungsgemeinschaft (SFB1123)
- Fondation Leducq (12CVD02)
- Universiteit van Amsterdam
- Bundesministerium für Bildung und Forschung
- Ministero della Salute
- Novo Nordisk Fonden (NNF16OC0021370, NNF14OC0011049, NNF15OC0016320)
- Exzellenzclusters Entzündungsforschung
- National Institutes of Health (UL1TR001070)
- Medical Research Council (MC_UU_12015/1, MR/N005813/1, MC_PC_13048, EU FP7, MR/L003120/1)
- Barts and The London School of Medicine and Dentistry
- National Heart, Lung, and Blood Institute (R01HL127564, K08HL114642, K01HL125751, R01HL107816)
- National Human Genome Research Institute (U01HG008672)
- National Cancer Institute (R25CA094880)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- coronary artery disease, ANGPTL4, lipoprotein lipase, SVEP1, missense mutations, loss-of-function mutations, gain-of-function mutations, myocardial infarction, triglyceride levels, PCSK9, LPA, genetic risk factors, triglyceride lowering
- MeSH terms
- Angiopoietin-Like Protein 4, Aged, Coronary Artery Disease, Female, Humans, Lipoprotein Lipase, Male, Middle Aged, Mutation, Risk Factors, Triglycerides, Cell Adhesion Molecules, Sequence Analysis, DNA, Mutation, Missense, Angiopoietins, Genotyping Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
